for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Alimera Sciences Inc

ALIM.OQ

Latest Trade

5.48USD

Change

-0.22(-3.86%)

Volume

1,459

Today's Range

5.48

 - 

5.65

52 Week Range

0.00

 - 

10.32

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
5.70
Open
5.65
Volume
1,459
3M AVG Volume
1.06
Today's High
5.65
Today's Low
5.48
52 Week High
10.32
52 Week Low
0.00
Shares Out (MIL)
5.03
Market Cap (MIL)
28.68
Forward P/E
-4.85
Dividend (Yield %)
--

Next Event

Q3 2020 Alimera Sciences Inc Earnings Release

Latest Developments

More

Alimera Sciences Signs Distribution Agreement With Medis Pharmaceutical To Sell Iluvien® In Austria And The Czech Republic

Alimera Sciences Signs Distribution Agreement With Nordic Prime

Alimera Sciences Announces Second Quarter 2020 Financial Results

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Alimera Sciences Inc

Alimera Sciences, Inc. (Alimera) is a pharmaceutical company. The Company is engaged in the research, development and commercialization of prescription ophthalmic pharmaceuticals. The Company operates through U.S. and International segment. The Company focuses on diseases affecting the back of the eye or retina. The Company's product is ILUVIEN, which is developed to treat diabetic macular edema (DME). DME is a disease of the retina that affects individuals with diabetes and can lead to severe vision loss and blindness. In the United States, Canada, Lebanon and the United Arab Emirates, ILUVIEN is indicated for the treatment of DME in patients who have been treated with a course of corticosteroids and did not have a rise in intraocular pressure (IOP). In the European Economic Area (EEA) countries, ILUVIEN is indicated for the treatment of vision impairment associated with DME considered insufficiently responsive to available therapies.

Industry

Biotechnology & Drugs

Contact Info

6120 Windward Pkwy Ste 290

ALPHARETTA, GA

30005-8897

United States

+1.678.9905740

http://www.alimerasciences.com/

Executive Leadership

C. Daniel Myers

Non-Executive Chairman of the Board

Richard S. Eiswirth

President, Chief Executive Officer, Director

Phil Jones

Chief Financial Officer

Philip Ashman

Chief Operating Officer, Senior Vice President - Commercial Operations Europe

David R. Holland

Chief Marketing Officer and Senior Vice President Corporate Communications and Managed Markets

Key Stats

2.00 mean rating - 4 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2017

0.0K

2018

0.0K

2019

0.1K

2020(E)

0.0K
EPS (USD)

2017

-4.950

2018

3.750

2019

-2.190

2020(E)

-1.150
Price To Earnings (TTM)
--
Price To Sales (TTM)
0.52
Price To Book (MRQ)
--
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
--
LT Debt To Equity (MRQ)
--
Return on Investment (TTM)
-16.46
Return on Equity (TTM)
-12.86

Latest News

Latest News

BRIEF-Alimera Sciences Initiates Landmark New Day Clinical Trial To Evaluate Iluvien As Baseline Therapy For Diabetic Macular Edema

* ALIMERA SCIENCES INITIATES LANDMARK NEW DAY CLINICAL TRIAL TO EVALUATE ILUVIEN® AS BASELINE THERAPY FOR DIABETIC MACULAR EDEMA

BRIEF-Alimera Sciences Reports Q1 2020 Financial Results

* ALIMERA SCIENCES ANNOUNCES FIRST QUARTER 2020 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

BRIEF-Alimera Sciences Pre-Announces Expected Top Line Revenue For Q1 2020

* ALIMERA SCIENCES PRE-ANNOUNCES EXPECTED TOP LINE REVENUE FOR Q1 2020 AND PROVIDES COVID-19 BUSINESS UPDATE

BRIEF-Alimera Sciences Says, Has Regained Compliance With NASDAQ Listing Rules - SEC Filing

* ON MARCH 6, RECEIVED LETTER FROM NASDAQ INFORMING THAT CO HAS REGAINED COMPLIANCE WITH NASDAQ LISTING RULES - SEC FILING Source text: (bit.ly/3cEClzx) Further company coverage:

BRIEF-Alimera Sciences Reports Fourth Quarter Results

* ALIMERA SCIENCES REPORTS RECORD FOURTH QUARTER AND 2019 RESULTS

BRIEF-Alimera Sciences Posts Q1 Loss Per Share Of $0.11

* Q1 REVENUE ROSE 48 PERCENT TO $9.8 MILLION Source text: (https://bit.ly/2KyoIEn) Further company coverage:

BRIEF-Alimera Sciences Enters Into $40 Mln Term Loan Agreement With Solar Capital

* ALIMERA SCIENCES INC- ENTERED INTO A $40 MILLION TERM LOAN AGREEMENT WITH SOLAR CAPITAL LTD

BRIEF-Alimera Sciences Inc reports qtrly loss per share ‍$0.08​

* Alimera Sciences Inc reports third quarter 2017 financial results

BRIEF-Alimera Sciences files for mixed shelf of up to $100 mln

* Alimera Sciences Inc files for mixed shelf of up to $100 million – SEC filing Source text - (http://bit.ly/2yCWftF) Further company coverage:

BRIEF-Alimera Sciences ‍announces Iluvien now available in Ireland​

* Alimera Sciences Inc - Announces Iluvien now available in Ireland Source text for Eikon: Further company coverage:

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up